利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

80 条记录 (耗时 0.031 秒)

    Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
    41.
    发明授权
    Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases 有权
    CCN3对CCN2的调控及其在纤维化，硬化等疾病中的治疗和诊断潜力

    公开(公告)号：US07780949B2

    公开(公告)日：2010-08-24

    申请号：US11329453

    申请日：2006-01-10

    申请人： Bruce L. Riser

    发明人： Bruce L. Riser

    IPC分类号： A61K49/00 ,  A61K49/14 ,  G01N33/53 ,  G01N33/50

    CPC分类号： G01N33/74 ,  A61K38/18 ,  G01N2333/475 ,  G01N2800/347

    摘要： The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and purified CCN3 protein or its fragments or isoforms (or combinations) of CCN3 can be potentially used in the treatment or prevention of these diseases by regulating the expression and/or activity of the CCN2 protein. The level of CCN3 in tissue or body fluids can also be used to predict, diagnose and/or follow the progression of diseases as well as to determine the effectiveness of therapeutic intervention.

    摘要翻译： 本发明公开了CCN3​​在与CCN2的过度表达相关的疾病中的作用，其包括但不限于肾脏疾病，纤维化和癌症。 CCN3的全长CCN3蛋白或其片段或同种型（或组合）参与这些疾病。 通过调节CCN2蛋白的表达和/或活性，CCN3的分离和纯化的CCN3蛋白或其片段或同种型（或组合）可以潜在地用于治疗或预防这些疾病。 组织或体液中CCN3的水平也可用于预测，诊断和/或跟踪疾病进展以及确定治疗干预的有效性。

    METHODS OF TREATING HIV-ASSOCIATED NEUROLOGICAL DISORDERS (HAND)
    44.
    发明申请
    METHODS OF TREATING HIV-ASSOCIATED NEUROLOGICAL DISORDERS (HAND) 有权

    公开(公告)号：US20220184036A1

    公开(公告)日：2022-06-16

    申请号：US17547472

    申请日：2021-12-10

    申请人： Rosalind Franklin University of Medicine and Science

    发明人： Johnny HE ,  Xiaojie ZHAO

    IPC分类号： A61K31/41 ,  A61K45/06 ,  A61P25/00 ,  A61K31/506

    摘要： In the present disclosure, doxycycline-inducible astrocyte-specific HIV Tat transgenic mice (iTat), a surrogate HAND model, were treated with PNU-125096, a positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR) and effects on Tat-induced behavioral impairments and neuropathologies were observed. This disclosure shows that PNU-125096 treatment significantly improved locomotor, learning and memory deficits of iTat mice while inhibited glial activation and increased PSD-95 expression in the cortex and hippocampus of iTat mice. α7 nAChR knockout eliminated the protective effects of PNU-125096 on iTat mice. In addition, inhibition of p38 phosphorylation by SB239063, a p38 MAPK-specific inhibitor, exacerbated Tat neurotoxicity in iTat mice. These findings demonstrated for the first time that α7 nAChR activation led to protection against HAND and suggest that α7 nAChR and PNU-125096 hold significant promise for development of therapeutics for HAND.

    Intelligent offloading insole device
    46.
    发明授权
    Intelligent offloading insole device 有权

    公开(公告)号：US10721993B2

    公开(公告)日：2020-07-28

    申请号：US15813613

    申请日：2017-11-15

    申请人： ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE ,  THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

    发明人： Noah J. Rosenblatt ,  Ryan Crews ,  Farid Amirouche

    IPC分类号： A43B17/03 ,  A43B13/20 ,  A43B3/00 ,  A43B17/02 ,  G05B15/02

    摘要： A plantar surface pressure offloading system includes an insole capable of coupling with a shoe and interfacing with a foot. A number of compressible bladders and pressure sensors are coupled to the insole. Each bladder has an adjustable compressibility, and each pressure sensor is configured to measure a pressure exerted on a respective portion of the foot. A controller of the system can perform, for each compressible bladder, a compressibility adjustment process including (i) receiving, from a respective pressure sensor associated with a respective bladder, a signal indicative of a pressure exerted on a respective portion of the foot, (ii) determining, based on the signal, that the pressure exerted on the respective portion of the foot exceeds a threshold pressure, and (iii) responsive to the determination, adjusting the compressibility of the respective bladder, thereby offloading pressure from the respective portion of the foot to a different portion of the foot.

    Antisense compounds targeting genes associated with cystic fibrosis
    47.
    发明授权
    Antisense compounds targeting genes associated with cystic fibrosis 有权

    公开(公告)号：US10544417B2

    公开(公告)日：2020-01-28

    申请号：US15835995

    申请日：2017-12-08

    申请人： Rosalind Franklin University of Medicine and Science

    发明人： Michelle L. Hastings

    IPC分类号： C12N15/113

    摘要： The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

    Antisense compounds targeting genes associated with cystic fibrosis
    48.
    发明授权
    Antisense compounds targeting genes associated with cystic fibrosis 有权

    公开(公告)号：US10525076B2

    公开(公告)日：2020-01-07

    申请号：US15835698

    申请日：2017-12-08

    申请人： Rosalind Franklin University of Medicine and Science

    发明人： Michelle L. Hastings

    IPC分类号： A61K31/712 ,  C12N15/113

    摘要： The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

    Methods and kits for diagnosing, prognosing and monitoring parkinson's disease
    50.
    发明授权
    Methods and kits for diagnosing, prognosing and monitoring parkinson's disease 有权

    公开(公告)号：US09970056B2

    公开(公告)日：2018-05-15

    申请号：US14870960

    申请日：2015-09-30

    申请人： Rosalind Franklin University of Medicine and Science

    发明人： Judith Ann Potashkin ,  Jose Alfredo Santiago

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/158

    摘要： Network-based meta-analysis of four independent microarray studies identified the hepatocyte nuclear factor (HNF4A), a transcription factor associated with gluconeogenesis and diabetes, as a central regulatory hub gene upregulated in blood of PD patients. In parallel, the polypyrimidine tract binding protein 1 (PTBP1), involved in the stabilization and mRNA translation of insulin, was identified as the most downregulated gene. Using both markers, PD patients were classified with 90% sensitivity and 80% specificity. Longitudinal performance analysis demonstrated that relative abundance of HNF4A and PTBP1 mRNAs significantly decreased and increased, respectively, in PD patients during 3 years follow up period. The inverse regulation of HNF4A and PTBP1 provides a molecular rationale for the altered insulin signaling observed in PD patients. The longitudinally dynamic biomarkers identified in this study may be useful for monitoring disease-modifying therapies for PD.